BioStack Raises $9.5M Seed Funding Led by Peak XV to Build Healthcare Data Infrastructure

Healthcare technology startup BioStack has raised $9.5 million in seed funding in a round led by Peak XV, alongside Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator.

The fresh capital will support the company's international expansion, technology development, and growth of its engineering and research teams.

Founded by Sanat Mishra, BioStack is building a healthcare data infrastructure network spanning the United States, India, Brazil and Argentina. The company says its network provides access to more than 100 million de-identified patient records, bringing together clinical information that is often fragmented across hospitals and healthcare systems.

Its platform aims to make this information more useful for medical research, drug development and the development of healthcare artificial intelligence models.

Connecting Fragmented Healthcare Records

Patient information is often spread across different systems, including hospital records, laboratory reports, medical imaging platforms, medication histories and clinical notes. These records can be difficult to combine into a consistent view of a patient's medical journey.

BioStack is developing infrastructure to connect these separate sources into longitudinal patient records. These records bring together information collected over time, including diagnoses, test results, treatments and patient outcomes.

A more connected view of clinical information can help researchers study how diseases progress, how patients respond to treatments and how medical outcomes differ across patient groups.

BioStack's infrastructure is designed to support these research needs by creating proprietary datasets from de-identified clinical information.

The company is building its network across four countries: the United States, India, Brazil and Argentina. According to BioStack, this network provides access to more than 100 million de-identified patient records.

The company has not disclosed a breakdown of these records by country or the number of healthcare institutions contributing data in the announcement provided.

Building Datasets for Medical Research and Healthcare AI

BioStack's platform is intended to support several research applications, including disease modelling, biomarker discovery, patient stratification and treatment response analysis.

Disease modelling helps researchers examine how conditions develop and progress. Biomarker discovery focuses on identifying measurable biological indicators that may help with disease detection, classification or monitoring.

Patient stratification involves grouping patients according to relevant characteristics, such as clinical profiles or potential treatment responses. Researchers can use these groups to investigate how different populations respond to therapies.

The platform is also designed to support the training and evaluation of healthcare AI models. Developing useful medical AI systems requires relevant clinical data and methods for assessing how reliably models perform on healthcare tasks.

BioStack's approach centres on creating structured datasets from clinical records that can support these research and development activities.

The company says it has aggregated several hundred thousand X-rays, MRI scans and CT scans, alongside millions of telehealth audio transcripts and other clinical records.

These datasets represent different forms of healthcare information, from medical images to conversations recorded during telehealth interactions. Bringing such information together can support a broader range of research questions than relying on a single type of clinical record.

However, the practical value of these datasets depends on factors such as data quality, representativeness, permitted use and the suitability of the information for a particular research task.

Data Privacy and Healthcare Workflows

Handling clinical information requires careful attention to privacy, security and the rules governing the use of patient data.

BioStack says its platform uses de-identified clinical records and incorporates workflows tailored to individual healthcare providers and their data privacy protocols.

De-identification is intended to reduce the risk of identifying individual patients from healthcare records. It does not eliminate every privacy risk, so appropriate safeguards and controls remain important when clinical information is processed, combined or used for research.

Healthcare providers may also have different requirements for accessing, transferring and using clinical information. BioStack says its platform incorporates workflows designed to accommodate these provider-specific protocols.

This capability is relevant to a business operating across multiple countries, where healthcare systems and data governance requirements may differ.

The company has not disclosed further technical details about its privacy architecture or the specific contractual arrangements governing each data source in the funding announcement provided.

Supporting Cancer Research in India

BioStack is also involved in connecting cancer patients in India with an investigational cancer vaccine programme.

This activity represents a more direct connection between its data infrastructure and clinical research. Investigational programmes require appropriate patient identification, clinical oversight and compliance with applicable research requirements.

The announcement does not provide further details about the vaccine programme, the number of patients involved or the outcomes achieved. It therefore remains unclear how large this initiative is or what results have been reported so far.

Still, the activity illustrates how healthcare data infrastructure can support work beyond building datasets for AI development, potentially connecting relevant patient populations with research opportunities.

Peak XV Leads the $9.5 Million Seed Round

The $9.5 million seed round was led by Peak XV, with participation from Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator.

The funding will support international expansion, further technology development and the growth of BioStack's engineering and research teams.

Expanding the company's data infrastructure across markets will require continued work on connecting clinical sources, structuring records and accommodating the requirements of different healthcare providers.

The investment also comes as healthcare organisations and medical technology developers seek access to datasets that can support research and the development of AI-enabled tools.

For BioStack, the challenge is to make fragmented clinical information more accessible for legitimate research purposes while maintaining appropriate safeguards around sensitive healthcare data.

What Comes Next for BioStack?

BioStack is positioning itself as a healthcare data infrastructure company serving medical research, drug development and healthcare AI development.

Its stated access to more than 100 million de-identified patient records across four countries gives the company a substantial stated data footprint. Its reported collection of medical imaging, telehealth transcripts and other clinical information also indicates a focus on multiple forms of clinical data.

The next phase will involve expanding its network, developing its technology and strengthening its engineering and research capabilities.

The company's progress will depend not only on the volume of records it can access, but also on the quality, usefulness and appropriate governance of the data it makes available for research.

As healthcare AI development continues, BioStack is betting that connecting fragmented clinical information can help researchers and developers work with richer datasets and investigate medical questions more effectively.